26,680.00
+1.27%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Abbott India
Its shares trade on NSE under the ticker ABBOTINDIA.NS. It has been listed since 3 November 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹69.29bn and net income of ₹15.52bn. At that date it held total assets of ₹65.02bn and shareholders' equity of ₹47.74bn.
Abbott India Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. The company provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. The company offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Nov 1994
- Employees
- 3,597
- Website
- abbott.co.in ↗
Leadership
Pay as last reported
- Mr. Munir Ahmed ShaikhNon-Executive Chairman of the Board₹3.2m
- Ms. Jyoti SaraphDirector - Finance
- Ms. Sangeeta ShettyChief Compliance Officer, Company Secretary, Associate Director - Secretarial
- Ms. Swati DalalManaging Director, Executive Director, since 2010
- Mr. Prithwish BanerjiCommercial Director - Womens Health, Metabolics and International Business
- Mr. Rajan KalantreDirector - Business Human Resources
- Dr. Jejoe KarankumarDirector - Medical Affairs
- Mr. Anuj MehraCommercial Director - NeuroLife, GenNext and Vaccines
- Mrs. Namita ShahAssociate Director - New Product Introductions and Therapy Area Strategy
- Ms. Richa TripathiAssociate Director - Sales Force Effectiveness, Project Management Office
- Ms. Alison DaviesAdditional Non-Executive Director
- Mr. Kaiyomarz MarfatiaNon-Executive Director₹2.3m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 56
- Social
- 58
- Governance
- 70
- Direct emissions (scope 1)
- 298.95 t
- Energy emissions (scope 2)
- 4,907.11 t
- Women in the workforce
- 9.91085%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Abbott India Ltd has a strong brand reputation in the pharmaceutical industry, which contributes to its competitive advantage. The company has a wide range of high-quality products in its portfolio, allowing it to cater to various healthcare needs. Abbott India Ltd also has a strong distribution network, enabling it to reach a large customer base efficiently. Furthermore, the company has a robust research and development division, consistently innovating and introducing new products to the market.
Weaknesses
- Abbott India Ltd currently faces challenges related to pricing pressures in the pharmaceutical sector. Additionally, the company heavily relies on a few key products for a significant portion of its revenue, making it vulnerable to market fluctuations and patent expirations. Furthermore, the company's high debt burden poses a risk to its financial stability, potentially limiting its growth opportunities.
Opportunities
- The growing healthcare sector in India presents significant opportunities for Abbott India Ltd. The increasing focus on preventive healthcare and the rising demand for specialized treatments create a favorable market environment for the company. Furthermore, Abbott India Ltd can explore strategic partnerships and acquisitions to expand its product portfolio and diversify its revenue streams. The expansion into untapped rural markets also holds potential for the company to reach a larger customer base.
Threats
- Abbott India Ltd faces threats from intense competition in the pharmaceutical industry, where rival companies often introduce similar products at competitive prices. The strict regulatory environment and frequent policy changes in the healthcare sector pose challenges for the company's operations. Moreover, the emergence of generic drugs and the potential loss of market exclusivity for key products can impact Abbott India Ltd's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.